ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
NT-proBNP in the very old population: reference values and heart failure specificity from the AugUR-study.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Clinical Value of NT-proBNP, sST2, and Galectin-3 in the Management of Heart Failure: From Diagnosis to Dynamic Monitoring: A Narrative Review.International journal of molecular sciences · 2026Review
- Association of high-sensitivity cardiac troponin T with all-cause and cardiovascular mortality in a mobile cohort of older adults aged 70 to 95 years - Results from the AugUR study.American journal of preventive cardiology · 2026Article
- Proteomics of aging: biomarkers for physiological systems and diseases.Frontiers in aging · 2026Review
- Sex-specific association of epicardial adipose tissue thickness and left ventricular hypertrophy in the older adults-cross-sectional results from the population-based AugUR study.Frontiers in cardiovascular medicine · 2026Article
- Lung Ultrasound Offers Fast and Reliable Exclusion of Heart Failure in the Emergency Department: A Prospective Diagnostic Study.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh NT-proBNP is an established marker of heart failure. However, old individuals have elevated values even when cardiovascularly healthy. Reference values remain scarce.
objectivesWe sought to provide reference values of NT-proBNP for the healthy old and very old population and the proportion above the AHA- and ESC-recommended rule-out cut-off for heart failure diagnosis in a non-acute setting (≥ 125 pg/mL).
methodsWe analyzed cross-sectional data from the population-based AugUR study of inhabitants ≥ 70 years of age. NT-proBNP was determined in serum. Cardiac morphology and function were evaluated by echocardiography.
resultsA total of 2304 subjects aged 70 to 95 years were analyzed (52% women; 35% ≥ 80 years). Median NT-proBNP increased by age group (70-74/75-79/80-84/ ≥ 85 years: 153.0/176.9/228.5/395.0 and 116.1/171.5/217.6/437.0 pg/mL for women or men, respectively); 68% had NT-proBNP ≥ 125 pg/mL. In a subgroup free of cardiovascular risk factors, renal failure, coronary artery disease, and atrial fibrillation (n = 685), 50% (70-79 years) and 70% (≥ 80 years) had NT-proBNP ≥ 125 pg/mL; 97.5% quantiles were considerably higher than 125 pg/mL (70-79 years: 559.5 or 424.5 for women or men; 80-95 years: 809.2 or 722.0 pg/mL for women or men). When further restricting to normal left ventricular mass, E/e' ratio, and ejection fraction (n = 65), 53% of subjects (70-79 years) or 50% (≥ 80 years) had NT-proBNP ≥ 125 pg/mL.
conclusionsNT-proBNP levels continue to rise in the very old population. More than 50% of healthy subjects aged 70 years and older have NT-proBNP values above the decision-making cut-off at 125 pg/mL, potentially causing unnecessary further diagnostics and referrals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.